PG vs RBGLY: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
PG is the larger of the two ($335.44B market cap): the incumbent the market prices for continued execution (19.50x forward earnings, beta 0.38). RBGLY is the smaller challenger ($43.45B), cheaper on forward earnings (14.64x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
PG vs RBGLY: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | PG | RBGLY | What it tells you |
|---|---|---|---|
| Market cap | $335.44B | $43.45B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 19.50 | 14.64 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 21.80 | 11.52 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.38 | 0.28 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 23% of range | 29% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 6.29 | 5.67 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: RBGLY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how PG and RBGLY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PG and RBGLY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PG and RBGLY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Procter & Gamble (PG) do?
Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. Its portfolio is organized into segments spanning fabric and home care (Tide, Ariel, Downy, Dawn, Febreze), baby, feminine, and family care (Pampers, Always, Bounty, Charmin), beauty (Olay, Pantene, Head & Shoulders, SK-II), grooming (Gillette, Venus), and health care (Crest, Oral-B, Vicks, Metamucil). P&G makes money selling these branded products through retailers, e-commerce, and other channels worldwide, relying on scale, marketing, and continual product innovation to command premium pricing and shelf space. The company deliberately pruned its portfolio over the past decade to focus on a smaller set of large, profitable, daily-use categories. Founded in 1837 and headquartered in Cincinnati, Ohio, P&G is a classic defensive blue chip and a Dividend King, prized for steady cash flow, pricing power, and an exceptionally long record of dividend increases.
What does Reckitt Benckiser Group plc (RBGLY) do?
Reckitt Benckiser Group plc sells everyday health and cleaning products in close to every country. It now reports two businesses. Core Reckitt holds four categories: Self Care (Mucinex, Nurofen, Strepsils, Gaviscon), Germ Protection (Dettol and Lysol), Household Care (Finish dishwasher products, Vanish stain removers and Harpic toilet cleaners) and Intimate Wellness (Durex). Mead Johnson Nutrition, which sells Enfamil and Nutramigen infant formula, sits outside the core and is treated as non-core while the company considers all options for it. In 2025 group net revenue was ~£14.2 billion, and like-for-like growth excluding Essential Home was 5.0%. In the March 2026 quarter, Core Reckitt's ~£2.6 billion of net revenue split as ~£1.09 billion from emerging markets, ~£873 million from Europe and ~£638 million from North America, and Mead Johnson added ~£531 million.
PG vs RBGLY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- PG drivers: Brand strength and pricing power; Defensive, recurring demand.
- RBGLY drivers: Emerging markets as the growth engine; Fixing Europe and North America.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: P&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives. For RBGLY, litigation is the risk that sets Reckitt apart from its peers.
PG or RBGLY: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick PG if you believe its drivers more; RBGLY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PG and RBGLY guides.
PG vs RBGLY: the full fundamentals
PG. P&G is a high-margin, cash-rich consumer-staples leader that commands a premium valuation for its brand strength, defensiveness, and unmatched dividend record. The financial profile is steady rather than fast-growing: modest organic growth, reliable margins, and consistent capital return funded by very strong free cash flow.
RBGLY. Reported revenue is falling because Essential Home left the group on December 31, 2025, which is why first-half 2026 net revenue (~£6.41 billion) came in below the prior year's ~£6.98 billion even as like-for-like sales grew 2.6%. Yahoo Finance shows RBGLY at ~11.5x trailing earnings, a figure flattered by disposal gains, and ~14x forward earnings, which is a lower multiple than many large consumer-staples peers. The forward yield of ~4.2% rests on a dividend that the company raised 5% for 2025 and again at the 2026 interim. The discount reflects slower growth in developed markets and the open-ended NEC litigation.
Headline figures (approximate, early 2026): PG shows revenue (ttm) ~$84 billion, operating margin ~24%, net margin ~18%, free cash flow ~$15+ billion annually; RBGLY shows net revenue (fy 2025, group) ~£14.2 billion, adjusted operating profit (fy 2025) ~£3.54 billion, 24.9% margin, net revenue (h1 2026) ~£6.41 billion, adjusted diluted eps (h1 2026) 152.1p, down 9.7%.
The bottom line: PG vs RBGLY
PG and RBGLY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined PG and RBGLY exposure against your real portfolio. It is not an investment adviser.
Wondering how PG or RBGLY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Procter & Gamble with AI
Connect the broker you already use and ask Walnut's AI how PG fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between PG and RBGLY?
+
Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. Reckitt Benckiser Group plc sells everyday health and cleaning products in close to every country. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is PG or RBGLY the better stock?
+
Neither is universally better. PG is the larger incumbent; RBGLY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, PG or RBGLY?
+
On forward P/E (as of October 2026), PG trades at 19.50x and RBGLY at 14.64x, so RBGLY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both PG and RBGLY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of PG vs RBGLY?
+
PG: P&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives. A large share of sales comes from outside the US, exposing earnings to a strong dollar and emerging-market currency swings. Input-cost inflation (commodities, energy, transportation) can pressure margins. Private-label competition and shifting retailer dynamics, including the bargaining power of large retailers, are persistent threats. The defensive profile also means the stock can lag sharply in strong bull markets, and its premium valuation leaves little room for execution missteps. RBGLY: Litigation is the risk that sets Reckitt apart from its peers. Mead Johnson and Abbott face more than 2,000 lawsuits in the US alleging that formula for premature babies is linked to necrotizing enterocolitis, a serious bowel disease. Mead Johnson has recently won: a federal bellwether jury found for it, a St. Louis jury cleared it in July 2026, and an Illinois appeals court threw out a $60 million verdict from March 2024 and sent the case back for retrial. Abbott has fared worse, including a $495 million verdict upheld on appeal in Missouri, which shows how large single awards can be. Reckitt denies that its products cause NEC, but more trials are ahead and a run of losses could cost far more than the reserves investors assume. Operating risks are also real. Core growth slowed to 1.3% in the March 2026 quarter, Europe is shrinking, Household Care fell 7.6%, and the cold and flu season can swing Self Care in any quarter. Russia sanctions changes and the Middle East conflict hit emerging markets in early 2026, and the transfer of the Russian business is still in progress. Higher oil prices could add ~£130 million to £150 million to input costs, and a Mead Johnson sale may fetch less than hoped while the lawsuits remain open. For US holders, RBGLY's dollar price moves with sterling, dividends are reduced by depositary fees, and OTC volume can be lighter than the London line.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell PG or RBGLY; figures are approximate and dated (as of October 2026). Verify current data before investing.